Abstract
Typical posterior reversible encephalopathy syndrome (PRES) is a clinical-neuroradiological entity characterised by bilateral white matter oedema, which is usually symmetrical and totally reversible in 2–3 weeks. A 46-year-old man presented with a persistent headache and visual blurring in the right eye. On admission, the clinical examination revealed minimal unsteadiness of gait and elevated blood pressure. A brain MRI showed a hyperintense signal on T2-weighted sequences in the whole brainstem, extended to the spinal cord (C2–C6), the left insula and the right cerebellum. When his blood pressure was controlled, his symptoms gradually improved. The follow-up MRI scan at 3 weeks revealed a dramatic regression of the hyperintense lesions on T2-weighted sequences. The differential diagnosis of PRES is very wide, especially in the case of conspicuous brainstem involvement. Treatable causes of white matter oedema should be always kept in mind to avoid misdiagnosis and prevent complications, such as intracranial haemorrhage.
Keywords: neurology, Brain stem/cerebellum, neuroimaging, neuro-oncology, radiology
Background
Typical posterior reversible encephalopathy syndrome (PRES) is a clinical-neuroradiological entity characterised by subcortical vasogenic oedema, with preferential involvement of the posterior brain regions.1 The most common clinical findings include headache, altered mental status, seizures, vomiting and visual disturbance.2–6 MRI demonstrates bilateral and symmetrical white matter oedema, which is usually reversible in 2–3 weeks.7 The diagnosis requires both clinical and radiological criteria and normalisation of the neuroimaging at follow-up. It has been proposed that several clinical conditions may play a role in triggering PRES: hypertension, immunosuppressive drugs, chemotherapy, transplantation, eclampsia, renal failure, sepsis and autoimmune diseases such as systemic lupus erythematosus or polyarteritis nodosa.1 8 9 Breakdown of the blood–brain barrier and endothelial dysfunction are considered the principal underlying mechanisms.1 However, the exact pathogenesis of PRES remains incompletely understood.8
We report an atypical case of PRES in a 46-year-old man with prominent brainstem involvement suggestive of malignancy.
Case presentation
A 46-year-old man was admitted with a month-long history of headache and visual blurring in the right eye. His medical history mentioned mononucleosis (the year before), gastro-oesophageal reflux, renal colic, frequent urination and appendectomy. He reported a family history of cardiovascular diseases (hypertension, ischaemic heart disease and cerebral ischaemia). He had not been on any regular medications. He was not a chronic alcohol user and he also denied smoking and sexual promiscuity.
On admission, the neurological examination revealed minimal unsteadiness of gait with no other cerebellar signs neither focal neurological deficits. Physical examination was unremarkable, except for elevated blood pressure (200/140 mm Hg).
Investigations
A brain MRI showed a hyperintense signal on T2-weighted sequences in the whole brainstem, extended to the spinal cord (C5–C6), the left insula and the right cerebellum (figure 1). Diffusion-weighted imaging (DWI) sequences demonstrated a vasogenic oedema. An intraparenchymal haemorrhage was found at the pontomedullary junction. There were patchy areas of signal enhancement in the pons as well as spinal leptomeningeal enhancement following the injection of contrast material on T1-weighted sequences (figure 1). Time-of-Flight Magnetic Resonance Angiography (MRA) was unremarkable, with no signs of vasculopathy. Neuroimaging data were consistent with a space-occupying lesion of the whole brainstem extended to the cervical spinal cord and supratentorial regions.
Figure 1.

MRI performed during hospitalisation. MRI performed during hospitalisation shows a hyperintense signal in the medulla oblongata (A), pons (B) and left insula (C) in FLAIR sequences; in (D) normal findings on MRI spectroscopy; hyperintense signal in the medulla oblongata to C5-6 in T2-weighted sequences (E); spinal leptomeningeal enhancement following the injection of contrast material on T1-weighted sequences (F). FLAIR, fluid attenuated inversion recovery.
Blood investigations showed polyglobulia, presence of serum anti-hepatitis C virus (HCV) antibodies and HCV-RNA positivity (830 000 UI/ml). There were no abnormalities in serum electrolytes, blood sugar, renal and liver function, thyroid function, urine analysis and coagulation profile. HIV infection was ruled out. ECG was in sinus rhythm.
An ophthalmological examination demonstrated a grade 3 hypertensive retinopathy. Visual field examination revealed centrocecal defects and a nasal scotoma in the right eye. Visual evoked potentials showed a bilateral prolongation of the latency of P100 waves.
Differential diagnosis
Possible differential diagnoses of T2-hyperintense brainstem lesions extended to the spinal cord include tumours (glioma and lymphoma), vasculitis, infections, osmotic demyelination syndrome, toxic leukoencephalopathy and neuromyelitis optica spectrum disorders (NMOSD).
The clinical presentation and MRI findings (figure 1) in our patient were consistent with an initial hypothesis of a space-occupying lesion. Then, he was referred to a neurosurgeon, who hypothesized a low-grade glioma; however, he did not recommend performing a biopsy, due to the localisation of the lesion. In addition, the initial diagnosis was questioned after MRI-spectroscopy (figure 1), which was not consistent with glioma. Infectious processes were excluded because of negativity of biochemical markers of inflammation. Osmotic demyelination syndrome and toxic leukoencephalopathy were also ruled out, since there was no history of electrolyte imbalance, correction of hyponatraemia or toxic agents’ exposure. Central nervous system (CNS) vasculitis linked to HCV infection was considered, but there were no mural thickening or vessel wall contrast enhancement on MRA; cryoglobulins were not assessed, but antinuclear antibodies and anti-neutrophil cytoplasmic antibodies were negative. Visual impairment and longitudinal-extended transverse myelitis with rostral involvement of the brainstem may be signs of NMOSD. However, our patient did not show increased signal within the optic nerves on T2-weighted sequences and did not fully meet the diagnostic criteria for NMOSD.10 Since the suspicion was too low, acquaporin-4 and myelin oligodendrocyte glycoprotein antibodies were not assessed.
Reversible cerebral vasoconstriction syndrome was also considered due to headache and focal intracerebral haemorrhage, but it seemed unlikely in absence of diffuse vasoconstriction on MRA.6
Recovering of symptoms after blood pressure control and improvement of the hyperintense T2-weighted lesions on a repeated MRI allowed a diagnosis of PRES associated with accelerated hypertension. In fact, even without typical symptoms of PRES, except for visual loss, clinical–radiological findings disappeared after normalisation of blood pressure.6
Treatment
On the first day of admission, the patient was started on ramipril 10 mg once a day. However, he had persistently elevated blood pressure and was still symptomatic. So that, 4 mg doxazosin and 30 mg nifedipine once daily were added. When his blood pressure was controlled, his symptoms gradually disappeared. Renal, renovascular and endocrine causes of secondary hypertension were excluded.
Outcome and follow-up
Blood pressure was controlled by day 8 of admission. Headache gradually improved as well as other clinical signs.
At 3-week follow-up the neurological examination was normal. A repeated brain MRI showed an almost complete resolution of the T2-hyperintense lesions. In particular, there were only some persistent centropontine alterations (figure 2). No enhancement was seen following contrast administration. The pontomedullary haemorrhage was seen again. These findings confirmed the diagnosis of atypical PRES with coincidental intraparenchymal haemorrhage.
Figure 2.

MRI at follow-up. MRI shows regression of the hyperintense lesions on T2-sequences, with complete resolution of the oedema and only a few persistent centro-pontine alterations (A, B).
At 2-year follow-up, the patient presented clinical and radiological stability. He was on ramipril 10 mg once daily and his blood pressure was within normal limits.
Discussion
The present paper describes an atypical case of PRES with prominent brainstem involvement in a 46-year-old man.
MRI is the gold standard for the diagnosis of PRES and should be performed as soon as possible. Since the first description in 1996,1 several radiological patterns of PRES have been reported,5 including asymmetrical and unilateral variants3 11 or involvement of atypical regions, such as brainstem and cerebellum.12–17 In typical PRES, neuroimaging usually reveals symmetric oedema in the subcortical white matter of parietal–occipital regions. Sparing of the calcarine and paramedian occipital lobe structures distinguishes PRES from bilateral infarction of the posterior cerebral artery.18 19 A key point is choosing the correct time to perform neuroimaging in order to demonstrate the presence of T2-hyperintense lesions, which disappear after removal of the causal factor. Many studies describe normal or non-specific findings when MRI is performed too early.4 On the other hand, if neuroimaging is abnormal, a too early repeated MRI could fail in highlighting a regression of the T2-hyperintensities.3 Symptoms of PRES usually resolve in 3–8 days, but MRI alterations may persist for several weeks. The ideal time of repeated brain imaging to document recovery is not clear.3 It seems advisable to repeat brain MRI at least 3 weeks after removing the causal factor of PRES.
Contrast enhancement can be variably present (figure 1). Since contrast enhancement is associated with the breakdown of the blood-brain barrier, it is especially expected in patients who are taking endothelium-toxic drugs, such as immunosuppressants.20 No relevant associations have been found between contrast enhancement and clinical outcome, so intravenous gadolinium-based contrast seems not necessary to evaluate the severity or extent of PRES.20 The presence or absence of contrast enhancement could be linked to the stage of the lesion, with cases lacking enhancement possibly being in a stage in which the blood–brain barrier has regained its integrity.20
The diagnosis of PRES can be complex in atypical cases (2%–10%) involving the brainstem, which have to be differentiated from other diseases, for example posterior circulation stroke.6 In these cases DWI sequences on brain MRI help to distinguish cytotoxic oedema, typical of ischaemic lesions, from vasogenic oedema, typical of PRES: cerebral infarction shows hyperintensity on DWI with low signal on the corresponding apparent diffusion coefficient (ADC) map while PRES shows the exact opposite.6 However, alterations in DWI sequences may also occur incase of PRES: an increase in T2 signal caused by increased water within regions of vasogenic oedema can cause slight DWI hyperintensity (the so-called T2-shine through). However, the ADC maps, which are not influenced by the T2 component, show normal or elevated signal intensity, as expected in vasogenic oedema.21
Concomitant brainstem or cerebellar involvement in PRES occurs in as many as 70% of patients, whereas only brainstem or cerebellar involvement is reported uncommonly.15 22 In these cases, despite the presence of extensive MRI abnormalities, patients usually show mild symptoms or signs of brainstem or cerebellar dysfunction.22 Although PRES typically occurs in the fifth and sixth decades of life, brainstem variants have been reported even in younger subjects in the fourth decade.22
Consistent with the literature data, our patient showed mild clinical symptoms associated with prominent MRI abnormalities, which initially led to a misdiagnosis of low-grade glioma. However, rapid reversibility of symptoms after controlling blood pressure aided in ruling out this hypothesis. Misdiagnosis of PRES as a brain tumour could be very dangerous and lead to unnecessary and invasive investigations, such as lumbar puncture, cerebral angiography, brain biopsy or even surgery.23–28
Wide varieties of medical conditions have been suggested as causes of PRES.7 We believe that accelerated hypertension was the triggering factor in our patient. In fact, even if he had no history of hypertension, ophthalmological examination revealed a hypertensive retinopathy, hinting a chronic hypertensive insult. Sustained and persistent hypertension may exceed the brain vessels’ autoregulatory reserve, leading to vasodilatation and vasoconstriction with increased permeability of the blood–brain barrier and consequent vasogenic oedema.29 30 However, 15%–20% of patients with PRES are normotensive or hypotensive and, among patients who are hypertensive, less than 50% have a mean arterial blood pressure above the upper limit of cerebral blood flow autoregulation.29 So that, some authors have suggested that endothelial dysfunction caused by hypertension or circulating toxins could have a pathogenic role in the syndrome.31 For example, cytokine release in immune disorders leads to increased vascular permeability, which possibly causes vasogenic oedema.29 It has been proposed that posterior cerebral circulation might be more vulnerable to a failure in autoregulation, due to less sympathetic innervation, thus explaining the frequent bilateral posterior involvement in PRES.29 30
Even when a possible triggering factor is found, the cause of PRES remains uncertain and the exact mechanism is still unknown.32
PRES can appear as a severe clinical condition, but recovery is usually rapid and complete.7 Nevertheless, in some cases PRES could have secondary complications due to reactive vasoconstriction. In a series by Lee et al follow-up neuroimaging after 2 weeks demonstrated residual foci of abnormalities, suggestive of small residual infarcts, in approximately one-fourth of patients.3 Lesions compatible with transient white matter oedema may evolve into persistent areas of leukomalacia, especially when treatment is delayed.33 Haemorrhages are considered an uncommon complication in PRES, ranging from 5% to 17% of cases.3 34 No significant difference in haemorrhage frequency has been found in patients having normal, mildly elevated or severely elevated blood pressure. The pathological mechanism of bleeding is still not understood. It has been proposed that haemorrhages could be the result of pial vessels rupture in severe hypertension or reperfusion injury in vasoconstriction.34
Permanent neurological deficits and even death have been reported, questioning the complete reversibility of this clinical entity.29 34 In this regard, our patient remained asymptomatic during the follow-up period. Intracranial haemorrhage on repeated brain MRI was the only sequel of the syndrome. Furthermore, recurrent PRES episodes can present in about 4% of cases.35
In conclusion, neuroimaging and clinical characteristics have a key role in making the correct and timely diagnosis of PRES, in order to avoid unnecessary investigations and prevent possible complications, such as intracranial haemorrhages.
It is important to exclude other possible differential diagnosis, especially in atypical cases of conspicuous brainstem involvement. In these circumstances, brain and spinal cord MRI is mandatory. When hypertension is concomitant to PRES, the management involves continuous blood pressure monitoring and rapid control of systemic blood pressure. Some authors recommend to treat ‘any degree of hypertension’ in the attempt to reduce the patient’s risk of complications.31 In the initial phase, blood pressure should be lowered no more than 25% in order to avoid ischaemic events.30 Labetalol and nircadipine are usually administered as first-line treatments in intensive care units; nitroglycerin should be avoided due to possible worsening of vasogenic oedema.29 36
When PRES occurs in normotensive patients, treatment consists of removing the possible triggering factor (ie, correcting metabolic abnormalities) and administering anticonvulsive medications if seizures occur.
There are no recommendations for specific anticonvulsive drugs or optimal duration of anticonvulsive therapy.29
Learning points.
Typical posterior reversible encephalopathy syndrome (PRES) is a clinical–neuroradiological entity with subcortical vasogenic oedema and preferential involvement of the posterior brain regions. MRI demonstrates bilateral widespread white matter alterations, which are reversible in 2–3 weeks.
Atypical variants of PRES could involve the brainstem and cervical spine, mimicking neoplastic lesions. To confirm a diagnosis of PRES, it is useful to repeat a brain MRI, in order to demonstrate an expected improvement of T2-weighted hyperintensities.
When hypertension is concomitant to PRES, the treatment involves continuous blood pressure monitoring and rapid control of systemic blood pressure.
Footnotes
VDS and MGR contributed equally.
Contributors: VDS and MVDA provided clinical care to the patient, conception and design, acquisition of the data, analysis and interpretation of the data; MGR and MO revised the article critically for intellectual content; all authors contributed to and have approved the final version of the manuscript.
Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests: None declared.
Patient consent for publication: Obtained.
Provenance and peer review: Not commissioned; externally peer reviewed.
References
- 1. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494–500. 10.1056/NEJM199602223340803 [DOI] [PubMed] [Google Scholar]
- 2. Kwon S, Koo J, Lee S. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Pediatr Neurol 2001;24:361–4. 10.1016/S0887-8994(01)00265-X [DOI] [PubMed] [Google Scholar]
- 3. Lee VH, Wijdicks EFM, Manno EM, et al. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol 2008;65:205–10. 10.1001/archneurol.2007.46 [DOI] [PubMed] [Google Scholar]
- 4. Pedraza RMP, Varum J. Posterior reversible encephalopathy syndrome: a review. Crit Care & Shock 2009;12:135–43. [Google Scholar]
- 5. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol 2008;29:1036–42. 10.3174/ajnr.A0928 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Roth C, Ferbert A. The posterior reversible encephalopathy syndrome: what's certain, what's new? Pract Neurol 2011;11:136–44. 10.1136/practneurol-2011-000010 [DOI] [PubMed] [Google Scholar]
- 7. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2007;28:1320–7. 10.3174/ajnr.A0549 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Gocmen R, Ozgen B, Oguz KK. Widening the spectrum of PRES: series from a tertiary care center. Eur J Radiol 2007;62:454–9. 10.1016/j.ejrad.2006.12.001 [DOI] [PubMed] [Google Scholar]
- 9. Le EM, Loghin ME. Posterior reversible encephalopathy syndrome: a neurologic phenomenon in cancer patients. Curr Oncol Rep 2014;16:383–91. 10.1007/s11912-014-0383-3 [DOI] [PubMed] [Google Scholar]
- 10. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177–89. 10.1212/WNL.0000000000001729 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Patel K, Durnford A, Owen N, et al. Posterior reversible encephalopathy syndrome mimicking a cerebral tumour. Case Rep Child Meml Hosp Chic 2012;2012:bcr1120115104 10.1136/bcr.11.2011.5104 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Kastrup O, Schlamann M, Moenninghoff C, et al. Posterior reversible encephalopathy syndrome: the spectrum of MR imaging patterns. Clin Neuroradiol 2015;25:161–71. 10.1007/s00062-014-0293-7 [DOI] [PubMed] [Google Scholar]
- 13. Chen DY-T, Tseng Y-C, Hsu H-L, et al. Teaching neuroimages: central variant of posterior reversible encephalopathy syndrome. Neurology 2014;82:e164 10.1212/WNL.0000000000000407 [DOI] [PubMed] [Google Scholar]
- 14. McKinney AM, Jagadeesan BD, Truwit CL. Central-variant posterior reversible encephalopathy syndrome: brainstem or basal ganglia involvement lacking cortical or subcortical cerebral edema. AJR Am J Roentgenol 2013;201:631–8. 10.2214/AJR.12.9677 [DOI] [PubMed] [Google Scholar]
- 15. Hebant B, Guegan-Massardier E, Triquenot-Bagan A, et al. Atypical MRI presentation of posterior reversible encephalopathy syndrome with predominant brainstem involvement. Acta Neurol Belg 2019;119:123–5. 10.1007/s13760-018-1055-0 [DOI] [PubMed] [Google Scholar]
- 16. Maalouf G, Mitry E, Lacout A, et al. Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab. J Neurol 2008;255:295–6. 10.1007/s00415-008-0692-2 [DOI] [PubMed] [Google Scholar]
- 17. Wijenayake Galagamage IDK, Sujith A, Kiringodage AK. Isolated pontine involvement in posterior reversible encephalopathy syndrome with coincidental acute ischaemic stroke. BMJ Case Rep 2019;12:e227132 10.1136/bcr-2018-227132 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Ni J, Zhou L-X, Hao H-lin, et al. The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: a retrospective series of 24 patients. J Neuroimaging 2011;21:219–24. 10.1111/j.1552-6569.2010.00497.x [DOI] [PubMed] [Google Scholar]
- 19. Singh RR, Ozyilmaz N, Waller S, et al. A study on clinical and radiological features and outcome in patients with posterior reversible encephalopathy syndrome (PRES). Eur J Pediatr 2014;173:1225–31. 10.1007/s00431-014-2301-y [DOI] [PubMed] [Google Scholar]
- 20. Karia SJ, Rykken JB, McKinney ZJ, et al. Utility and significance of gadolinium-based contrast enhancement in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2016;37:415–22. 10.3174/ajnr.A4563 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Ay H, Buonanno FS, Schaefer PW, et al. Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology 1998;51:1369–76. 10.1212/WNL.51.5.1369 [DOI] [PubMed] [Google Scholar]
- 22. Cruz-Flores S, de Assis Aquino Gondim F, Leira EC. Brainstem involvement in hypertensive encephalopathy: clinical and radiological findings. Neurology 2004;62:1417–9. 10.1212/01.WNL.0000120668.73677.5F [DOI] [PubMed] [Google Scholar]
- 23. Wurm G, Parsaei B, Silye R, et al. Distinct supratentorial lesions mimicking cerebral gliomas. Acta Neurochir 2004;146:19–26. 10.1007/s00701-003-0151-x [DOI] [PubMed] [Google Scholar]
- 24. Jurcić V, Ferluga D, Jeruc J, et al. Hypertensive encephalopathy mimicking brainstem tumour in psychiatric patient. Folia Neuropathol 2004;42:37–41. [PubMed] [Google Scholar]
- 25. Rath JJG, Koppen H, Treurniet FEE, et al. Reversible posterior leucoencephalopathy syndrome mimicking low-grade glioma: differentiation by positron emission tomography. Clin Neurol Neurosurg 2011;113:785–7. 10.1016/j.clineuro.2011.08.001 [DOI] [PubMed] [Google Scholar]
- 26. Tchaou M, Modruz N, Agoda-Koussema LK, et al. Two unusual aspects of posterior reversible encephalopathy syndrome mimicking primary and secondary brain tumor lesions. Case Rep Radiol 2015;2015:1–5. 10.1155/2015/456217 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Wong K, Lee M, Davis ID, et al. Posterior reversible encephalopathy syndrome mimicking brain metastases in a patient with metastatic transitional cell carcinoma. Asia Pac J Clin Oncol 2017;13:e534–6. 10.1111/ajco.12510 [DOI] [PubMed] [Google Scholar]
- 28. Morina D, Ntoulias G, Maslehaty H, et al. Posterior reversible encephalopathy syndrome mimicking cerebral metastasis: contraindication for biopsy. Clin Pract 2014;4:632 10.4081/cp.2014.632 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol 2015;14:914–25. 10.1016/S1474-4422(15)00111-8 [DOI] [PubMed] [Google Scholar]
- 30. Fittro K, Dizon R. Understanding posterior reversible encephalopathy syndrome. J Am Acad Physician Assist 2018;31:31–4. 10.1097/01.JAA.0000534980.69236.81 [DOI] [PubMed] [Google Scholar]
- 31. Bartynski WS, Boardman JF, Zeigler ZR, et al. Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. AJNR Am J Neuroradiol 2006;27:2179–90. [PMC free article] [PubMed] [Google Scholar]
- 32. Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol 2008;29:1043–9. 10.3174/ajnr.A0929 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Antunes NL, Small TN, George D, et al. Posterior leukoencephalopathy syndrome may not be reversible. Pediatr Neurol 1999;20:241–3. 10.1016/S0887-8994(98)00148-9 [DOI] [PubMed] [Google Scholar]
- 34. Rykken JB, McKinney AM. Posterior reversible encephalopathy syndrome. Semin Ultrasound CT MR 2014;35:118–35. 10.1053/j.sult.2013.09.007 [DOI] [PubMed] [Google Scholar]
- 35. Sweany JM, Bartynski WS, Boardman JF. ‘Recurrent’ posterior reversible encephalopathy syndrome: report of 3 cases—PRES can strike twice! J Comput Assist Tomogr 2007;31:148–56. [DOI] [PubMed] [Google Scholar]
- 36. Finsterer J, Schlager T, Kopsa W, et al. Nitroglycerin-aggravated pre-eclamptic posterior reversible encephalopathy syndrome (PRES). Neurology 2003;61:715–6. 10.1212/01.WNL.0000080369.87484.06 [DOI] [PubMed] [Google Scholar]
